One-liner#

Hyperlipidemia management centers on ASCVD risk stratification to guide statin intensity (high-intensity for established ASCVD, LDL ≥190, or diabetes with risk factors), achieving LDL targets (<70 mg/dL for ASCVD, <100 for moderate risk), and adding non-statin therapies (ezetimibe, PCSK9 inhibitors) when targets not met.

Quick nav#

• Definition and epidemiology
• Pathophysiology
• Clinical presentation
• Diagnostic workup
• Treatment
• Patient education
• Prognosis and monitoring
• Special populations
• When to refer
• Smartphrase snippets
• Related pages

Definition and epidemiology#

Diagnostic criteria#

Lipid categories (ATP III/ACC-AHA):

• LDL cholesterol: Optimal <100; near optimal 100-129; borderline high 130-159; high 160-189; very high ≥190 mg/dL
• HDL cholesterol: Low (increased risk) <40 men/<50 women; high (protective) ≥60 mg/dL
• Triglycerides: Normal <150; borderline 150-199; high 200-499; very high ≥500 mg/dL (pancreatitis risk)
• Non-HDL cholesterol: Total minus HDL; target <130 (or <100 if high risk); better predictor than LDL when TG elevated

Diagnosis requires: Fasting lipid panel (9-12 hour fast) preferred for accurate TG; non-fasting acceptable for LDL screening.

Epidemiology#

• Prevalence: ~94 million US adults have total cholesterol ≥200 mg/dL; ~28 million have LDL ≥160 mg/dL
• Only ~55% of adults who qualify for statins are taking them
• Leading modifiable risk factor for ASCVD (along with HTN, smoking, diabetes)
• LDL is causal for atherosclerosis—every 39 mg/dL reduction reduces CV events by ~22%
• Familial hypercholesterolemia affects 1 in 250; often undiagnosed

Pathophysiology#

Mechanism (clinical understanding)#

LDL and atherosclerosis:

1. LDL particles penetrate arterial endothelium and become trapped in subendothelial space
2. Oxidized LDL triggers inflammatory response—macrophages engulf oxidized LDL, becoming foam cells
3. Foam cells accumulate → fatty streak → atherosclerotic plaque
4. Plaque grows over decades; stable plaques cause stable angina; vulnerable plaques rupture → ACS

Why LDL lowering works:

• Statins reduce hepatic cholesterol synthesis → upregulate LDL receptors → increased LDL clearance
• Lower LDL = less substrate for plaque formation
• Statins also stabilize existing plaques (reduce lipid core, thicken fibrous cap, reduce inflammation)
• “Lower is better”—no threshold below which LDL reduction stops being beneficial

Triglycerides:

• Very high TG (≥500) increases pancreatitis risk—primary treatment indication
• Moderate TG elevation (150-499) contributes to residual CV risk; icosapent ethyl reduces events

Familial hypercholesterolemia (FH):

• Autosomal dominant; LDL receptor mutations → severely elevated LDL from birth
• Heterozygous FH: LDL typically 190-400 mg/dL; affects 1 in 250
• Untreated: 50% of men have MI by age 50; 30% of women by age 60

How to explain to patients#

“Cholesterol is a waxy substance in your blood. Your body needs some, but too much of the bad kind (LDL) builds up in your artery walls like rust in a pipe. Over time, this narrows your arteries and can cause heart attacks and strokes.”

“Think of LDL as delivery trucks dropping off cholesterol in your arteries. The more trucks (higher LDL), the more buildup. Statins reduce the number of trucks, so less cholesterol gets deposited.”

“The good news is that lowering your LDL not only slows new buildup—it can actually stabilize the deposits already there, making them less likely to cause a heart attack.”

Clinical presentation#

Characteristic symptoms#

Hyperlipidemia itself is asymptomatic—detected through screening blood tests. Symptoms only occur from complications (ASCVD) or very severe elevations.

Signs of severe/familial hyperlipidemia:

• Xanthomas: cholesterol deposits in tendons (Achilles, extensor tendons) or skin
• Xanthelasma: yellowish plaques on eyelids
• Corneal arcus: white/gray ring around cornea (significant if age <45)

Physical exam findings#

• Often completely normal
• Tendon xanthomas (Achilles, extensor tendons)—highly specific for FH
• Xanthelasma—not specific; can occur with normal lipids
• Signs of ASCVD: carotid bruits, diminished peripheral pulses

Red flags#

Suspect familial hypercholesterolemia if:

• LDL ≥190 mg/dL (especially if untreated)
• Tendon xanthomas
• Family history of premature ASCVD (men <55, women <65)
• Personal history of premature ASCVD

Urgent evaluation needed if:

• Triglycerides ≥500 mg/dL (pancreatitis risk)
• New symptoms of ASCVD (chest pain, TIA symptoms, claudication)

Diagnostic workup#

Initial evaluation#

Lipid panel (fasting preferred):

• Total cholesterol, LDL, HDL, triglycerides
• Calculate non-HDL cholesterol (total minus HDL)
• Fasting (9-12 hours) preferred for accurate TG

Calculate 10-year ASCVD risk (Pooled Cohort Equations):

• Uses age, sex, race, total cholesterol, HDL, SBP, BP treatment, diabetes, smoking
• Risk categories: Low <5%; Borderline 5-7.5%; Intermediate 7.5-20%; High ≥20%

Additional labs:

• TSH: hypothyroidism causes secondary hyperlipidemia
• BMP: CKD affects lipid metabolism and statin dosing
• LFTs: baseline before statin (not required to repeat unless symptoms)
• A1c: diabetes is ASCVD risk enhancer

Confirmatory testing#

Lipoprotein(a) [Lp(a)]:

• Genetically determined; not affected by lifestyle or statins
• Elevated Lp(a) (≥50 mg/dL) is independent CV risk factor
• Check once in lifetime; useful for risk refinement in borderline cases

Coronary artery calcium (CAC) score:

• Useful for risk refinement in intermediate-risk patients (7.5-20% 10-year risk)
• CAC = 0: low risk, may defer statin; CAC ≥100: statin indicated
• Not useful if already high-risk or on statin

When to refer for specialist workup#

• Suspected familial hypercholesterolemia (LDL ≥190, tendon xanthomas, family history)
• LDL not at goal despite maximally tolerated statin + ezetimibe
• Statin intolerance (unable to tolerate ≥2 statins)
• Severe hypertriglyceridemia (TG ≥500) not responding to initial therapy

What NOT to order#

• Routine LFTs during statin therapy: Only check if symptoms
• CK levels routinely: Only check if muscle symptoms
• Repeat CAC score: Once is enough; doesn’t change with treatment
• Advanced lipid panels (NMR, VAP) routinely: Standard lipid panel sufficient for most

Treatment#

Goals of therapy#

LDL targets by risk category (ACC/AHA 2018):

Risk enhancers (favor statin in borderline/intermediate risk):

• Family history of premature ASCVD
• LDL ≥160 mg/dL persistently
• CKD (eGFR 15-59)
• Chronic inflammatory conditions (RA, psoriasis, HIV)
• Lp(a) ≥50 mg/dL

Non-pharmacologic management#

Dietary modifications (can reduce LDL 10-15%):

• Reduce saturated fat to <7% of calories (limit red meat, full-fat dairy)
• Eliminate trans fats (partially hydrogenated oils)
• Increase soluble fiber to 10-25 g/day (oats, beans, psyllium)—reduces LDL 5-10%
• Mediterranean diet: reduces CV events independent of LDL (PREDIMED trial)

Exercise: 150 min/week moderate aerobic; modest LDL effect but improves HDL, TG, overall CV risk

Weight loss: Every 10 lb lost reduces LDL ~5-8 mg/dL; greater effect on TG

Pharmacologic management#

Statin therapy (first-line):

Non-statin therapies:

Patient counseling points#

For statins:

• “This is one of the most important medicines for preventing heart attacks and strokes.”
• “Muscle aches occur in about 5-10% of people. If you have new muscle pain, let me know—but don’t stop without calling first.”
• “Statins are very safe for your liver. We don’t need routine liver tests unless you have symptoms.”

For lifestyle:

• “Diet and exercise help, but for most people with high cholesterol, medication is needed to reach goal.”

Monitoring and follow-up#

Initial phase: Lipid panel at 4-12 weeks after starting or changing therapy; assess adherence and tolerability

Stable phase: Lipid panel annually once at goal; no routine LFT or CK monitoring

Statin intolerance management:

• Try different statin (rosuvastatin and pravastatin have lower myopathy rates)
• Try lower dose or alternate-day dosing
• If unable to tolerate any statin: ezetimibe + bempedoic acid; consider PCSK9i if high risk

Patient education#

What is this condition?#

Cholesterol is a waxy substance in your blood. Your body makes cholesterol and you also get it from food. Some cholesterol is needed, but too much of the bad kind builds up in your arteries.

LDL is the bad cholesterol. It sticks to your artery walls and forms blockages over time. HDL is the good cholesterol. It helps remove bad cholesterol from your arteries.

High cholesterol has no symptoms. You cannot feel it. The only way to know is through a blood test.

What you can do#

Take your cholesterol medicine every day, even when you feel fine. It works best when taken regularly.

Eat less saturated fat. This means less red meat, butter, cheese, and fried foods. Choose fish, chicken, and olive oil instead.

Eat more fiber. Oatmeal, beans, and fruits help lower cholesterol.

Stay active. Walk or exercise most days of the week.

When to seek care#

Call your doctor if you have muscle pain or weakness that is new or unusual.

Call your doctor if you have dark urine or yellowing of your skin or eyes.

Go to the emergency room if you have chest pain, sudden weakness on one side, or trouble speaking.

Questions to ask your doctor#

What is my LDL number and what should it be?

Am I at high risk for a heart attack or stroke?

Do I need medicine or can I try diet and exercise first?

What side effects should I watch for?

Prognosis and monitoring#

Expected course#

With treatment:

• High-intensity statins reduce LDL by 50% or more
• Every 39 mg/dL reduction in LDL reduces major CV events by ~22%
• NNT for high-intensity statin in secondary prevention: ~25 over 5 years

Without treatment:

• Progressive atherosclerosis
• Increased risk of MI, stroke, PAD

Monitoring parameters#

Complications to watch for#

Statin-related:

• Myalgias (5-10%): muscle aches without CK elevation
• Myopathy (<0.1%): muscle pain with CK >10x ULN; stop statin
• New-onset diabetes: ~10% increased risk; benefits outweigh risk

Disease-related:

• ASCVD events if LDL not controlled
• Pancreatitis if TG ≥500 mg/dL

Special populations#

Elderly/geriatric#

Treatment considerations:

• Statins reduce CV events in elderly (age 65-75) with similar relative risk reduction
• Age >75: less trial data, but reasonable to continue if tolerating and has ASCVD or high risk
• Primary prevention in age >75: individualize based on life expectancy, functional status
• More sensitive to drug interactions and myopathy

Beers criteria considerations:

• Statins are NOT on Beers list—safe in elderly
• Avoid high-dose simvastatin (>20 mg) with interacting drugs

Deprescribing: Consider stopping if limited life expectancy (<1-2 years) or severe frailty

Chronic kidney disease#

Medication adjustments:

Special considerations:

• CKD is ASCVD risk enhancer—favors statin therapy
• Higher myopathy risk in CKD—start lower doses
• Fenofibrate: reduce dose or avoid; can worsen renal function

Other populations#

Diabetes: All diabetics age 40-75 should be on statin; SGLT2i and GLP-1 RA have CV benefits independent of lipids

Familial hypercholesterolemia: High-intensity statin + ezetimibe first-line; PCSK9i often needed; screen first-degree relatives

Women of childbearing potential: Statins contraindicated in pregnancy (Category X); counsel on contraception

Polypharmacy considerations:

• Simvastatin: many CYP3A4 interactions—max 20 mg or avoid with diltiazem, verapamil, amiodarone
• Rosuvastatin, pravastatin: minimal CYP interactions—preferred in complex regimens
• Gemfibrozil + statin: increased myopathy risk—avoid; fenofibrate safer

When to refer#

Specialist referral criteria#

Lipid specialist/cardiologist referral:

• Suspected familial hypercholesterolemia
• LDL not at goal despite maximally tolerated statin + ezetimibe
• Statin intolerance (unable to tolerate ≥2 statins)
• Severe hypertriglyceridemia (TG ≥500) not responding to therapy

Urgency levels#

Smartphrase snippets#

Hyperlipidemia, controlled: Hyperlipidemia on high-intensity statin with LDL at goal. No myalgias. Continue current regimen; repeat lipid panel in 1 year.

Hyperlipidemia, not at goal: Hyperlipidemia with LDL above goal for ASCVD. Adding ezetimibe to statin. Recheck lipids in 6-8 weeks.

Hyperlipidemia, new diagnosis: New diagnosis hyperlipidemia. Starting statin based on ASCVD risk. Discussed lifestyle modifications. Recheck lipids in 4-12 weeks.

Related pages#

• Chest Pain (complaint) — hyperlipidemia is major risk factor for CAD
• Coronary Artery Disease (problem) — secondary prevention with high-intensity statin; LDL target <70 mg/dL
• Heart Failure (problem) — statin indicated if ischemic etiology
• Hypertension (problem) — shared CV risk factor; often co-managed
• Atrial Fibrillation (problem) — shared CV risk factors
• Type 2 Diabetes (problem) — all diabetics 40-75 should be on statin (coming soon)